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Abstract
Diabetic kidney disease (DKD) is a major cause of end-stage renal disease. Intensive blood glucose and blood pressure con-
trol, particularly using inhibitors of the renin-angiotensin system, have long been mainstays of therapy in patients with DKD. 
Moreover, new anti-hyperglycemic drugs have recently shown renoprotective effects and this represents a major progress 
in the management of DKD. However, the risk of progression is still substantial and additional drugs are required. Recent 
preclinical studies have identified novel therapeutic targets that may optimize renoprotection in the near future. Besides 
strategies aimed to reduce oxidative stress and inflammation in the kidney, novel extra-renal approaches targeting stem cells, 
extracellular vesicles, and the microbiota are on the horizon with promising preclinical data. Herein, we will review these 
lines of research and discuss potential clinical applications. Given the poor yield of experimental studies in DKD in the past 
years, we will also discuss strategies to improve translation of preclinical research to humans.
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Introduction
The prevalence of diabetes is increasing worldwide to epi-
demic proportions. In 2019, approximately 464 Mio. people 
were living with diabetes and the number is predicted to 
exceed 700 Mio. by 2045. Diabetic kidney disease (DKD) is 
the commonest cause of end-stage renal disease (ESRD) and 
in the United States over 50% of subjects requiring dialysis 
and/or kidney transplantation have diabetes. Furthermore, 
the development of DKD dramatically increases the risk 
of cardiovascular both morbidity and mortality and most 
patients with DKD die for cardiovascular diseases.
Both albuminuria and relentless renal function decline 
are characteristic DKD features. The increased glomeru-
lar permeability to proteins leading to the development of 
albuminuria is due to podocyte injury, comprising nephrin 
and podocin downregulation, foot process effacement, 
and apoptosis. Progressive accumulation of extracellular 
matrix components (ECM) in both the mesangium and the 
tubulointerstitium plays a key role in renal function decline, 
eventually resulting in ESRD [1]. Besides the classical albu-
minuric phenotype, a new “non-albuminuric” phenotype 
characterized by eGFR decline without albuminuria has 
emerged in the last decades, indicating that DKD progres-
sion toward ESRD may occur through distinct albuminuric 
and non-albuminuric pathways [2]. Nevertheless, higher 
albuminuria still remains the major risk factor for progres-
sive DKD [3, 4].
Mechanistically, the metabolic insult of hyperglycemia 
plays a key role in the pathogenesis of DKD by inducing 
oxidative stress and inflammation and by altering important 
metabolic [polyol pathway, exosamine pathway, advanced 
glycation end product (AGE) formation] and intracellular 
signalling pathways [i.e. protein kinase C (PKC), mitogen-
activated protein (MAP) kinases, JAK-STAT, Notch], lead-
ing to podocyte injury and renal fibrosis. Cytokines released 
by both renal resident cells and inflammatory cells infiltrat-
ing the kidney are important mediators of the renal damage. 
Among them the prosclerotic cytokines TGF-β1 and CTGF, 
the vasoactive peptides angiotensin II and endothelin A, and 
the proinflammatory cytokines monocyte chemoattractant 
protein-1 (MCP-1), and tumor necrosis factor-α (TNF-α) are 
of particular relevance.
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In last 30 years, optimal control of both blood glucose and 
blood pressure and RAS inhibition have been the only avail-
able strategies for the treatment of DKD. In this period, pre-
clinical research in experimental models of DKD has greatly 
improved our understanding of renal pathophysiology and 
also identified new promising therapeutic targets. However, 
new drugs arising from these studies failed to prove efficacy 
and safety in randomized clinical trials (RCTs) in humans. 
Recently, RCTs that were performed to prove cardiovascu-
lar safety of new anti-hyperglycaemic agents revealed that 
SGLT2 inhibitors (SGLT2i) [5–7] and GLP-1 receptor ago-
nists [8, 9] have unforeseen anti-proteinuric and/or renopro-
tective effects in DKD. In particular, treatment with SGLT2i 
on the top of traditional RAS inhibition has proven to sig-
nificantly reduce not only albuminuria, but also the decline 
in renal function and the associated cardiovascular risk in 
patients with established DKD [6]. In addition, atrasentan, 
which blocks the potent vasoconstrictor peptide endothelin 
A, showed renoprotective effects in a carefully selected sub-
group of patients with type 2 diabetes [10].
These clinical findings represent a major turning point 
in the treatment of DKD and suggest greater efficacy of 
drugs acting upon the hemodynamic abnormalities of DKD 
that are known to interact with the metabolic pathways to 
promote renal function loss. Increased glomerular capillary 
pressure is an early feature in diabetes and an important 
mechanism of progression in all chronic kidney diseases. 
The particular efficacy of RAS blockers in the treatment 
of DKD is due to their ability to reduce not only systemic 
blood pressure, but also glomerular capillary pressure via 
vasodilation of the efferent arteriole. Similarly, SGLT2i 
are believed to slow DKD progression predominantly by 
reducing glomerular capillary pressure via vasoconstriction 
of the afferent arteriole [11]. Therefore, RAS blockers and 
SGLT2i appears to have complementary positive effects on 
renal hemodynamic.
Although results from recent RCTs on DKD represent a 
major step forward in the effort to retard the progression of 
DKD, a residual risk still remains and it has been calculated 
that 2% of patients will still progress to ESRD every year 
even after addition of SGLT2i to current therapy [12]. There 
is thus great interest to identify novel strategies for treat-
ment. Herein, we will review novel lines of research that 
have recently emerged in the field of experimental DKD and 
their potential clinical applications (Fig. 1). Moreover, given 
the poor outcome of preclinical research in DKD so far, we 
Fig. 1  Current and emerging treatments for diabetic kidney disease. 
Both the metabolic and the hemodynamic insults play a key role in 
the pathogenesis of diabetic kidney disease by inducing oxidative 
stress, inflammation, activation of deleterious signalling pathways 
and transcription factors, and release of cytokines in the kidney. Cur-
rently pharmacological agents for the management of DKD and novel 
both renal and extra-renal potential targets for treatment are shown. 
GLP1 glucagon-like peptide 1, SGLT2, sodium–glucose cotrans-
porter 2, RAS renin–angiotensin system, MSCsmesenchymal stem 
cells, EVs extracellular vesicles, ASK1 apoptosis signal-regulating 
kinase 1, Nrf2 nuclear factor erythroid 2-related factor 2, NOX nico-
tinamide adenine dinucleotide phosphate oxidase, CB1R cannabinoid 
receptor type 1, CB2R cannabinoid receptor type 2, MCP-1 monocyte 
chemoattractant protein-1, CCR2 CC chemokine receptor 2, NF-κB 
Nuclear Factor Kappa B
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will also discuss strategies to improve translation of animal 
research to humans.
Oxidative stress
Hyperglycemia causes the formation of an excess of reactive 
oxygen species (ROS) in both the mitochondria and the cyto-
sol. Although ROS play an important role in intracellular 
signalling, their accumulation can lead to oxidative stress 
and induce damage of critical cellular components, such as 
DNA and proteins. Oxidative stress is considered a leading 
mechanism of injury in DKD and contributes to both renal 
fibrosis and function decline [13]. Several antioxidants, such 
as coenzyme Q10 (ubiquinone), mitochondrial ubiquinone 
(MitoQ), resveratrol, and ascorbic acid have been tested in 
experimental DKD, but their efficacy appears modest and 
there are concerns about potential toxicity [14]. Recently, the 
NADPH oxidase family and ASK1 have emerged as interest-
ing and promising novel targets in DKD.
NADPH oxidase
NADPH oxidase (Nox) is an enzyme that produces ROS. 
In neutrophils, Nox plays an important role in antimicro-
bial host defence and inflammation as the Nox-mediated 
release of high concentrations of ROS aids in the clearance 
of invading bacteria [13]. Nox is also present in other cell 
types, where its role is less understood. Among the five Nox 
isoforms present in humans Nox4 and Nox5 are the most 
relevant to DKD.
In animal models of DKD, expression of Nox4 is 
enhanced in the glomeruli and Nox4 is a major renal source 
of ROS [15, 16]. Intervention studies in experimental dia-
betes have shown that administration of Nox4 antisense 
oligonucleotides [17] as well as both global and podocyte-
specific Nox4 deletion [18, 19] protected the kidney from 
diabetes-induced glomerular damage. Notably, treatment 
with GKT137831, a specific Nox1/4 inhibitor, markedly 
reduced albuminuria, oxidative stress, and kidney fibrosis, 
replicating the beneficial effects of Nox4 deletion [18]. In 
humans, GKT137831 failed to show a significant reduction 
in albuminuria. However, rodents differ from humans in the 
expression of Nox isoforms and do not express Nox5 and 
this may explain why promising preclinical results could not 
be replicated in humans. Indeed, preliminary data indicate 
that Nox4 deletion is no longer protective in transgenic ani-
mals expressing humans Nox5.
Although Nox-5 is more difficult to investigate in pre-
clinical studies because it is absent in rodents, recent data 
highlighted the importance of Nox5 in DKD. In patients 
with DKD, glomerular Nox5 expression was enhanced 
predominantly in podocytes and mesangial cells [20, 21]. 
Exposure of cultured mesangial cells to both high glucose 
and TGF-β1 induced Nox5, while exposure of podocytes to 
angiotensin II increased the expression of the Nox5v2 splice 
variant, providing a possible mechanism for Nox5 upregula-
tion in vivo.
The potential pathogenic role of Nox5 in DKD has 
been investigated in transgenic animals. Mice expressing 
human Nox5 exclusively in podocytes developed podo-
cyte injury, albuminuria, oxidative stress, inflammation 
and this was accelerated in the presence of streptozotocin 
(STZ)-induced diabetes [20]. In animal models of type 1 
diabetes, expression of Nox5 exclusively in vascular muscle 
cells and mesangial cells exacerbated diabetes-induced renal 
inflammation, mesangial expansion, and glomerulosclerosis 
[21, 22]. Moreover, diabetic Akita mice, expressing Nox5 
in endothelial cells, showed worsening of albuminuria and 
inflammation [22]. In vitro studies have cast light on the 
potential mechanisms of the deleterious effects of the Nox5 
in glomerular cells. Exposure to angiotensin II of podocytes 
expressing Nox5 induced actin cytoskeletal reorganization 
and activation of Rac GTPase, which promotes cell motil-
ity, via a Nox5-dependent mechanism [20]. This is relevant, 
as podocyte effacement requires cytoskeleton remodelling, 
foot process movement over the GBM, and slit diaphragm 
reconstruction and it is thus considered a migratory event. 
Moreover, mesangial cell exposure to high-glucose and/or 
TGF-β induced a significant upregulation of MCP-1, NF-κB, 
PKC-α and PKC-β and this was partially mediated by Nox5 
[21]. Besides to be downstream targets of Nox5, PKC-α and 
PKC-β mediate the phosphorylation of Nox5 and enhance 
Nox5 activity in a positive feedback loop. Therefore, Nox5 
and PKC interact in a bidirectional manner to exacerbate 
renal injury.
Collectively, these data from studies in experimental 
diabetes and cultured glomerular cells suggest a beneficial 
effect of Nox5 blockade in DKD and provide the ration-
ale for the development of specific Nox5 inhibitors. Stud-
ies examining Nox5 in animal models where this isoform 
is endogenously expressed, such as rabbits, are currently 
on-going.
ASK1
Apoptosis signal-regulating kinase 1 (ASK1) is a redox-
sensitive serine threonine kinase that activates the MAP 
kinases p38 and c-Jun and induces apoptosis, inflammation, 
and fibrosis in response to oxidative stress.
A recent study has identified ASK1 as a key factor in 
oxidative stress-induced kidney damage in diabetes [23]. 
ASK1 activity was enhanced in renal biopsies from patients 
with DKD. Treatment with the ASK1 inhibitor GS-444217 
reduced albuminuria, eGFR decline, and renal structural 
injury in a mouse model of DKD. Notably, combination 
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therapy with GS-444217 and enalapril provided even greater 
renoprotection [23].
Clinical trials of ASK1 inhibitors were recently per-
formed in patients with either nonalcoholic steatohepatitis 
(NASH) or DKD. In a multicenter phase 2 trial, treatment 
of patients with NASH and stage 2–3 liver fibrosis with the 
ASK1 inhibitor selonsertib was effective in reducing liver 
fibrosis [24]. However, a phase 2 trial evaluating safety and 
efficacy of selonsertib in adults with type 2 diabetes and 
moderate-to-advanced DKD failed to meet the primary end-
point as after 48 weeks of treatment eGFR did not differ in 
patients treated with selonsertib and placebo [25]. Moreover, 
selonsertib therapy did not modify albuminuria. However, 
selonsertib had an unexpected acute inhibitory effect on cre-
atinine tubular secretion, leading to an acute and reversible 
drop in eGFR in the first weeks of the study without changes 
in measured GFR [25]. This was likely a confounder dur-
ing the trial and a recent exploratory post-hoc analysis sug-
gested that between 4 and 48 weeks the highest selonsertib 
dose slowed DKD progression compared to placebo. Further 
studies are, however, required to dissect between tubular and 
glomerular effects of selonsertib and to exclude the pos-
sibility that selonsertib effect on eGFR is merely related to 
interference with creatinine tubular handling.
Inflammation
In the past two decades, growing evidence demonstrated a 
critical role of inflammation in both the pathogenesis and the 
progression of DKD. Renal monocyte infiltration occurs in 
both human and experimental DKD. Moreover, expression 
of cell adhesion molecules, chemokines, and proinflamma-
tory cytokines is increased in the renal tissues of diabetic 
patients. Several transcription factors (NF-ĸB, Nrf2) and 
inflammatory cytokines (MCP-1, TNF-α) were studied in 
the context of DKD and proposed as potential targets for 
therapy.
Bardoxolone methyl that activates the potent antioxidant 
and anti-inflammatory transcription factor Nrf2a was tested 
in a clinical trial (BEACON) in patients with DKD [26]. 
The RCT was prematurely terminated because of an excess 
fluid overload and heart failure (HF) in participants with 
elevated baseline levels of B-type natriuretic peptide (BNP), 
likely because of an effect of bardoxolone on the endothelin 
pathway. However, this line of research has not been com-
pletely abandoned and RCTs (TSUBAKI and AYAME) are 
currently on-going in patients at lower risk of fluid overload 
based on their both clinical and BNP response to escalating 
doses of bardoxolone methyl, an enrichment strategy similar 
to that was also employed in the SONAR trial. Moreover, 
SGLT2i lower the risks of HF and it would be of interest to 
explore the effect of a combined therapy with SGLT2i and 
bardoxolone methyl.
Another inflammatory target that emerged from preclini-
cal research in animal models of DKD is the chemokine 
MCP-1.
MCP‑1
MCP-1 is expressed by both resident glomerular cells and 
infiltrating monocytes. MCP-1 binds to the CC-chemokine 
receptor-2 (CCR2) and induces monocyte both recruitment 
and activation.
Several diabetes-related insults and mediators, such as 
high glucose, angiotensin II, advanced glycation end prod-
ucts (AGEs), mechanical stretch, TGF-β1, and TNF-α are 
potent MCP-1 inducers in glomerular cells. Consistent with 
this, MCP-1 is overexpressed within the glomeruli in exper-
imental diabetes. MCP-1 can contribute to the onset and 
progression of DKD by fuelling local inflammation through 
monocyte recruitment [27]. Furthermore, the MCP-1 recep-
tor CCR2 is also expressed by mesangial cells and podocytes 
[28–30] and MCP-1 may contribute to the development of 
DKD by directly inducing deleterious effects in resident glo-
merular cells. Indeed, in mesangial cells MCP-1 enhances 
ICAM-1 expression, increases fibronectin production, and 
partially mediates high glucose-induced TGF-β1, fibronec-
tin, and collagen type IV production. Moreover, in podocytes 
MCP-1 induces nephrin loss, apoptosis via TGF-β1, and 
podocyte migration [27]. The deleterious effects of MCP-1 
in podocytes are likely enhanced in DKD as podocyte CCR2 
expression is markedly increased in patients with type 2 dia-
betes and overt DKD.
Studies in experimental diabetes have convincingly dem-
onstrated a causative role of the MCP-1/CCR2 system in the 
pathogenesis of DKD. In experimental models of diabetes, 
MCP-1 deletion prevented the development of albuminuria, 
nephrin downregulation, and ECM overexpression [29, 31]. 
Moreover, gene transfer of the 7ND gene, a N-terminal dele-
tion mutant of human MCP-1, improved glomerulosclerosis 
in iNOS transgenic diabetic mice [32] and diminished diabe-
tes-induced glomerular hypertrophy and glomerulosclerosis 
in STZ-induced diabetic rats [33].
These promising results led to the development of phar-
macological agents blocking the MCP-1/CCR2 system that 
were then tested in experimental models. In db/db mice, the 
CCR2 antagonists RS504393 and RS102895 improved insu-
lin resistance and reduced macrophage infiltration and albu-
minuria [34]. In diabetic mice expressing human CCR2, oral 
administration of the CCR2 antagonist CCX140-B decreased 
albuminuria and glomerular hypertrophy, increased podo-
cyte numbers, but also improved glycaemic control [35].
More recently, phase 2 RCTs targeting the MCP-1/CCR2 
system have been performed in humans. In patients with 
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DKD, treatment with the CCR2 antagonist CCX140-B on 
the top RAS blockade decreased albuminuria, particularly 
in subjects with overt proteinuria [36]. Similarly, addi-
tion to standard therapy of emapticap pegol (NOX-E36), 
a Spiegelmer that specifically binds and inhibits MCP-1, 
improved albuminuria without significant side effects [36] 
and the CCR2 blocker, DMX-200 (propagermanium) is cur-
rently under investigation. However, in clinical studies in 
type 2 diabetes blockade of the MCP-1/CCR2 system also 
improved HbA1c, likely because of reduced inflammation 
in the pancreatic islet and/or the adipose tissue. Therefore, 
the beneficial effects of MCP-1/CCR2 blockade on albumi-
nuria may be partially due to amelioration of blood glucose 
control. Long-term clinical studies are awaited to clarify 
the potential clinical relevance of the MCP-1/CCR2 system 
as novel target in the treatment of DKD. In this regard, it 
would be important to establish blockade of the MCP-1/
CCR2 system still retain benefit when given in addition to 
SGLT2i/GLP-1RA.
The endocannabinod system
The endogenous cannabinoids, anandamide (AEA) and 
2-arachidonoylglycerol (2-AG), bind to the cannabinoid 
receptor 1 (CB1R) and 2 (CB2R). The endocannabinoid 
system (ECS) is predominantly expressed by the central 
nervous system (CNS) and by peripheral organs involved in 
the control of metabolism. However, recent studies suggest 
a role of the ECS in the kidney and in particular in DKD. 
CB1R is overexpressed by podocytes in both human and 
experimental DKD, while podocyte CB2R expression under-
goes downregulation in patients with advanced DKD. This 
is likely due to both hyperglycemia and glomerular capil-
lary hypertension as exposure to high glucose or angiotensin 
II enhances CB1R in podocytes, while mechanical stretch, 
mimicking glomerular capillary hypertension, decreases 
CB2R expression [37].
CB1R signalling increases oxidative stress, inflammation, 
and fibrogenesis, while CB2R has opposite effects. There-
fore, an imbalance between glomerular CB1R and CB2R 
signalling within the glomeruli can contribute to enhance 
oxidative stress, inflammation, and fibrosis in the context 
of diabetes. Consistent with this, studies in knockout/trans-
genic animals have shown that albuminuria and nephrin loss 
are induced in non-diabetic animals overexpressing CB1R 
[38], exacerbated in diabetic mice lacking CB2R [39], and 
ameliorated in diabetic mice lacking CB1R exclusively in 
podocytes [40].
On the clinical point of view are of particular relevance 
the results of studies in experimental diabetes using drugs 
that modulate the ECS. Both peripheral CB1R antagonists 
and CB2R agonists reduced albuminuria, prevented loss of 
slit-diaphragm proteins, and ameliorated glomerular fibro-
sis [41–43]. Moreover, dual therapy with the peripheral 
CB1R blocker AM6545 and the CB2R agonist AM1241 
showed greater efficacy than single therapy in diminishing 
albuminuria, inflammation, and renal fibrosis [44]. Notably, 
CB1R blockade also reversed changes in both albuminuria 
and renal function in animals with established albuminuria 
[43, 45]. Mechanistically, modulation of the ECS appears to 
prevent albuminuria by preventing nephrin loss and podo-
cyte apoptosis, while the beneficial effect on renal fibrosis 
is likely due reduced release of prosclerotic and pro-inflam-
matory factors [46].
These pre-clinical studies have opened the way to a novel 
area of research with potential clinical impact in humans. 
The use of peripherally restricted CB1R antagonists that 
do not cross the blood–brain barrier and are thus devoid of 
central side effects, is very promising in human DKD. These 
compounds are currently under early stage clinical develop-
ment with the aim of providing proof of safety and toler-
ability, including CNS safety. Moreover, compounds that 
are both CB1R antagonists and CB2R agonists may provide 
additional therapeutic benefits [46]. However, CB1R and 
CB2R can form heterodimers and their signalling pathways 
are deeply intertwined; therefore, further research is required 
to better elucidate their relationship and combined effects in 
order to avoid undesirable and/or off-target effects.
The gut microbiota
The gut microbiota comprises a set of microorganisms liv-
ing in the gut in symbiosis with the human host. In recent 
years, the gut microbiota has gained increasing interest and 
has been implicated in the pathogenesis of a vast array of 
diseases, including chronic kidney disease (CKD) and dia-
betes [47]. Changes in gut microbiota composition, accu-
mulation of microbiota-derived metabolites, interruption of 
intestinal barrier function, and chronic inflammation have all 
been reported in CKD. However, evidence linking the gut 
microbiota to DKD is still limited.
A small case–control study has shown greater relative 
abundance of Proteobacteria, Verrucomicrobia, and Fuso-
bacteria phyla in patients with DKD stage 4–5 compared 
to healthy controls and this was associated with enhanced 
circulating levels of lipopolysaccharides (LPS) and mark-
ers of inflammation [48]. Another study reported that 
higher faecal amount of Escherichia-Shigella and lower 
amount of Prevotella represent a sort of microbiota sig-
nature of DKD as it can distinguish among patients with 
type 2 diabetes those with and without biopsy-proven 
DKD [49]. Enterobacteriaceae and Proteobacteriaceae 
may be linked to DKD because they favour production of 
toxic metabolites that are normally cleared by the kidney 
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(uremic toxins). Moreover, they enhance the transloca-
tion of bacterial products and LPS into the circulation by 
increasing gut permeability. On the contrary, Prevotel-
laceae may be protective because they maintain the gut 
barrier function and reduce local inflammation by enhanc-
ing short-chain fatty acid (SCFAs) production [47].
An elegant study has recently described a novel link 
between the gut microbiota and DKD [50]. Gut microbes, 
expressing the enzyme tyrosine phenol-lyase (TPL), syn-
thesize phenol from dietary l-tyrosine. After absorption, 
phenol is metabolized by the liver into phenyl sulfate 
(PS), which is then secreted by proximal tubular cells. 
In experimental model of diabetes, treatment with PS 
induced podocyte hypertrophy, foot-process effacement, 
GBM thickening, inflammatory, and fibrosis, while treat-
ment with TPL inhibitors (2-aza-tyrosine, l-meta tyros-
ine) diminished both PS and creatinine levels without sig-
nificantly altering the microbial taxonomic balance. The 
observation that podocyte exposure to PS reduced glu-
tathione levels suggests that PS can contribute to DKD by 
increasing podocyte susceptibility to both oxidative stress 
and mitochondrial dysfunction. These findings may be rel-
evant to human DKD as in a cohort of 87 patients with 
type 2 diabetes and microalbuminuria plasma PS levels at 
baseline were a predictor of albuminuria progression at the 
2-years follow up even after adjustment for risk factors.
Other uremic toxins besides PS have been implicated in 
the progression of renal disease. Indoxyl sulfate (IS) and 
p-cresyl sulfate (PCS) are produced at the intestinal level 
by proteolytic microbes and then excreted in the urine by 
active tubular secretion. As kidney function declines, IS 
and PCS progressively accumulate in blood and may con-
tribute to DKD progression. Indeed, exposure of podo-
cytes to IS decreased both cell viability and expression 
of podocyte-specific genes, while it increased expression 
of both cytokine and chemokine expression. Furthermore, 
exposure of proximal tubular cells to IS and PCS induced 
epithelial to mesenchymal transition with overexpression 
of transcription factors associated with interstitial fibrosis 
and glomerulosclerosis [51]. It is thus temping to specu-
late that changes in the diet aimed to reduce microbiota-
derived uremic toxins may help reduce the rate of progres-
sion in advanced stage of DKD.
Although these preliminary data suggest a possible 
contribution of gut dysbiosis to the development and 
progression of DKD, further studies are required to gain 
a better understanding of the relationship between the 
human microbiome and renal pathophysiology. In particu-
lar, studies in larger cohorts of DKD patients using new 
approaches, such as metagenomics and metaproteomics, 
are essential to establish whether the gut microbiome may 
represent a novel target of the treatment of DKD.
Mesenchimal stem cells and extracellular 
vesicles
Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are self-renewing and 
multipotent progenitors that can differentiate into vari-
ous lineages. Over the past decade, intervention studies 
in animal models of DKD have proven the therapeutic 
potential of MSCs obtained from different sources, such 
as bone marrow (bm-MSCs), adipose tissue (ad-MSCs) 
and umbilical cord (uc-MSCs).
Administration of bm-MSCs via the renal artery 
decreased urinary albuminuria and improved renal func-
tion in STZ-induced diabetic rats with established DKD. 
This effect was paralleled by amelioration of diabetes-
induced podocyte loss, foot processes effacement, and 
downregulation of nephrin and podocin [52]. In a similar 
experimental model, intravenous infusion of bm-MSCs 
also reverted glomerulosclerosis, ECM deposition, and 
diminished macrophage infiltration and pro-inflammatory 
cytokines levels [53]. More recently, a study performed 
on type 1 diabetic mice has shown that bm-MSCs lim-
ited inflammation-related injury through the phenotypic 
switch of macrophage from a pro-inflammatory (M1) to 
anti-inflammatory (M2) phenotype [54]. It is worth noting 
that with the exception of the paper by Wang et al. in the 
aforementioned studies an amelioration of blood glucose 
has been also observed in MSCs-treated diabetic animals. 
Therefore, it is not clear whether MSCs act directly on the 
kidney or their beneficial effects are secondary to blood 
glucose lowering.
Although bone marrow is a rich source of MSCs, har-
vesting the bone marrow is an invasive procedure. Moreo-
ver, quantity, differentiation potential, and maximal life 
span of MSCs decline with the donor’s age. Therefore, 
several groups have tested the renoprotective effect of 
MSCs isolated from alternative and more accessible 
sources. Park et  al. demonstrated that treatment with 
uc-MSCs prevented renal injury and reduced mesangial 
expansion without affecting blood glucose levels in rats 
with STZ-induced diabetes [55]. Another study showed 
that uc-MSCs had a synergic effect in combination with 
resveratrol in improving renal function and podocyte num-
ber in Non-Obese Diabetic (NOD) mice independently by 
blood glucose levels [56]. Ad-MSCs provide a clear advan-
tage over bm-MSCs as they can be easily and repeatable 
harvested using minimally invasive techniques with low 
morbidity and their proliferation capacity does not decline 
with the age of the donor [57]. Repeated intravenous injec-
tions of ad-MSCs attenuated glomerulus hypertrophy and 
urinary protein excretion in STZ-induced diabetic rats 
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[58]. Moreover, Takemura et al. showed that transplan-
tation of ad-MSCs under the renal capsule of Spontane-
ously Diabetic Torii fatty rats attenuates glomerular and 
tubular injury to a greater extend compared to ad-MSCs 
administrated per intravenous route [59]. Finally, Lee SE 
et al. have shown that treatment with ad-MSCs prevented 
albuminuria and tubular epithelial cell injury via induc-
tion of the Arginase-1, a marker of M2 macrophages, and 
subsequent improvement of mitochondrial function [60]
Although these pre-clinical studies in DKD suggest that 
MSC-based therapy may represent a novel promising tool 
for DKD treatment, the experimental design of these studies 
is heterogeneous in terms of cell types, doses, administra-
tion route, diabetes duration, making it difficult to translate 
these findings into clinical practice. In addition, the use of 
MSCs has several limitations. As demonstrated by pre-clin-
ical studies, MSCs show minimal homing to the kidney and 
have limited survival in the kidney environment. Moreover, 
MSCs have poor expansion capacity in vitro and undergo 
senescence, which affects cell replication and differentiation 
capacity. In addition, MSC expansion in vitro for extended 
periods of time can confer risk of chromosomal instability 
and malignant transformation [61]. Finally, MSCs can differ-
entiate into undesired lineages as reported by Kunter U et al., 
showing “maldifferentiation” of intraglomerular MSCs into 
adipocytes accompanied by glomerular sclerosis [62].
MSC‑derived cytokine and extracellular vesicles
Emerging evidence shows that the efficacy of MSCs in 
ameliorating DKD is mainly due to MSC release of solu-
ble factors and extracellular vesicles (EVs) [63]. Consistent 
with this, Nagaishi et al. demonstrated that the beneficial 
effect of bm-MSCs in promoting renal damage repair and 
reducing macrophage infiltration, interstitial fibrosis, and 
glomerular injury in experimental DKD was reproduced 
by treatment with MSC conditioned media [64]. Moreover, 
LV et al. showed that conditioned media from bm-MSC 
inhibited the TGF-β/Smad prosclerotic pathway in mesan-
gial cells exposed to a high glucose milieu. This beneficial 
effect was abrogated by an antibody against bone morphoge-
netic protein-7 (BMP-7), suggesting that BMP-7 secreted by 
MSCs was involved. Using a similar experimental approach, 
the same group also demonstrated that in mesangial cells 
exposed to high glucose, hepatocyte growth factor (HGF) 
released by bm-MSC reduced TGF-β up-regulation and 
inhibited oxidative stress. Furthermore, Li D. et al. found 
that ad-MSCs prevented high glucose-induced podocyte 
both injury and apoptosis through secretion of epithelial 
growth factor (EGF). Finally, glial cell line–derived neu-
rotrophic factor (GDNF) released by ad-MSC prevented 
podocyte damage by restoring high glucose-induced synap-
topodin downregulation [63].
Besides soluble factors, extracellular vesicles (EVs) both 
exosomes (Exos) and microvesicles (MVs), may also mimic 
the effect of their parent cells via the horizontal transfer of 
functional microRNAs (miRNAs), mRNAs, and proteins to 
target cells. Several studies have shown that treatment with 
MSC-EVs is safe and has renoprotective effects in models 
of DKD. In diabetic animals, treatment with bm-MSC-Exos 
abolished apoptosis and tubular epithelial cells (TEC) dam-
age, improved renal function, and reduced renal fibrosis by 
acting on the mTOR signalling pathway and autophagy [65]. 
Urine-derived MSC-Exos prevented both podocyte and TEC 
apoptosis by suppressing caspase-3 overexpression in STZ-
induced diabetic rats [66]. More recently Jin et al. showed 
that ad-MSC-Exos reduced proteinuria and podocyte apop-
tosis in db/db mice. Mechanistically, ad-MSC-Exos reversed 
high glucose-induced apoptosis by enhancing the expres-
sion of miR-486, which inhibits the Smad1/mTOR signal-
ling pathway in podocytes [67]. Finally, bm-MSC-EVs and 
human liver-derived MSC (HLSC) EVs administered in a 
therapeutic-like regimen inhibit the progression of the func-
tional and morphological dysfunction caused by DKD [68] 
by reducing high glucose-induced both collagen and TGF 
overexpression in mesangial cells via the horizontal transfer 
of functional miR-222 [69].
Overall, these data indicate that EVs may represent an 
effective genetic information transfer agent that supports a 
series of biological processes and has therapeutic potential. 
On the clinical point of view, the use of MSC-derived EVs 
in place of MSCs has several advantages. EVs overcome 
concerns posed by MSCs as tumorigenicity, viral infection, 
cellular rejection, and mal-differentiation. Recent evidence 
also suggests that EVs can be used as drug delivery vec-
tors to treat and target specific cell types [70]. However, 
there are still many problems to address before EV therapy 
could be use in clinical practice. Since the properties of EVs 
are directly related to the conditions under which they are 
produced and the cells that produce them, it is essential to 
establish the characteristics of EVs from different sources 
for the repeatability and safety of subsequent applications. 
Moreover, a better understanding of EV mechanism action 
and complexity of their cargo need to be obtained prior to 
their use in humans. In addition, regulatory requirements for 
large-scale manufacturing and quality control are a precondi-
tion for clinical trials of EVs.
Implications for translational research
Although the novel lines of research in experimental DKD 
described above are very interesting, we cannot forget that 
in the past 20 years drugs that appeared very promising 
based on preclinical studies failed to prove efficacy and/
or safety in RCTs in humans. Paradoxically, novel drugs 
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for the treatment of DKD have recently come from RCTs 
designed for a different purpose. Indeed, the first evidence 
of SGLT2i efficacy in reducing albuminuria and preventing 
renal function loss was obtained in RCTs aimed to assess 
the non-inferiority of SGLT2-i compared to traditional 
anti-hyperglycaemic drugs in terms of cardiovascular out-
come [9]. The tradition bench to bedside approach has thus 
been inverted and we are currently trying to understand the 
molecular mechanisms underlying the positive effects of 
SGLT2i and GLP-1RA on the kidney after proving their 
clinical benefit in humans.
Important limits in the design of experimental studies 
may explain the low yield of translational research in DKD. 
To improve translation efficiency, the design of preclinical 
studies should better match that of RCTs (Fig. 2). Experi-
mental studies should be performed not only in young and 
lean animals with type 1 diabetes, but also in old and obese 
animals with type 2 diabetes as most DKD cases are old and 
obese patients with type 2 diabetes. Moreover, we should 
choose animal models that develop substantial renal injury 
and significant renal function loss to better mimic human 
DKD. Preclinical studies should set strict criteria for ran-
domisation with defined threshold of eGFR, albuminuria, 
and HbA1c. Safety and efficacy of potential therapeutic 
agents should be evaluated starting from the onset of DKD 
and/or albuminuria rather than at the onset of diabetes and 
secondary prevention/reversal studies should replace pri-
mary prevention studies. As eGFR is a major determinant 
of the primary endpoints used in RCTs and relevant for 
drug approval, assessment of eGFR in pre-clinical models 
is crucial and experimental drugs should prove efficacy 
not only in reducing albuminuria, but also eGFR decline. 
Finally, interventional drug should prove efficacy when they 
are given on top of current standard therapy with blood glu-
cose lowering drugs and both RAS and SGLT2 inhibition.
On the other hand, human RCTs also have limitations 
that contribute to increase the gap between pre-clinical and 
clinical research. Both structural and ultrastructural abnor-
malities are usually explored extensively in experimental 
models, but they are rarely assessed in human RCTs. Indeed, 
the diagnosis of DKD is purely based on the presence of 
albuminuria and/or eGFR loss in subjects affected by dia-
betes. Nonetheless, available histological studies in humans 
have shown large structural heterogeneity among patients 
clinically defined as affected by DKD. Particularly in older 
patients with type 2 diabetes, other insults besides diabe-
tes itself, such hypertension, vascular disease, and previous 
subclinical renal injury, may contribute to the renal dam-
age and significantly modify the course of the disease and 
the rate of progression towards ESRD. This heterogeneity 
is also present among patients recruited in RCTs and may 
significantly affect the response to treatment. Therefore, 
renal biopsies should be performed more often in RCTs in 
DKD (at least in subgroups) to better correlate clinical and 
structural outcomes and gain a better insight on underlying 
mechanisms of drug action. Moreover, novel enrichment 
study designs may be employed to identify drugs that are 
effective in specific subgroups of patients. In particular, 
subjects can be selected prior to randomisation based either 
on their individual response to the drug or on the positivity 
Fig. 2  Changes in the design of both experimental and clinical studies that may help improve translation of animal research to humans
Journal of Nephrology 
1 3
to relevant biomarkers. Finally, clinical studies on SGLT2i 
have shown that these compounds reduce eGFR in the short-
term, but have important reno-protective effects after longer 
follow-up. Therefore, novel potential drugs should not be 
dismissed based on preliminary underpowered short-term 
studies as longer duration of treatment may be required to 
reveal benefit.
These changes in the design of both experimental and 
clinical studies may help improve translation of animal 
research to humans and they are instrumental to further 
reduce the risk of DKD both onset and progression.
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